Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of ...

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine ...

Key Takeaways. Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer. Testing is usually incorporated at diagnosis or ...

New president DeMark Liggins has served with the SCLC for over 10 years. The Southern Christian Leadership Conference (SCLC) has promoted its vice president, DeMark Liggins, to lead the esteemed ...

Amgen AMGN announced that the FDA has granted accelerated approval to tarlatamab for pre-treated advanced small cell lung cancer (ES-SCLC). Tarlatamab is a delta-like ligand 3 targeting Bispecific ...

The benefit of prophylactic cranial irradiation in small cell lung cancer (SCLC) might be limited to patients with preexisting brain metastases, suggesting a role for active surveillance instead ...